StockData
Fennec Pharmaceuticals Inc. logo

Fennec Pharmaceuticals Inc. (FENC) stock

FENCNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 7/3088% above fair value
$13.58+0.82 (+6.43%)

Close on Nov 17, 2026Market cap $476.21MP/E –Yield –

Fennec Pharmaceuticals price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

Fennec Pharmaceuticals's price to sales ratio was 6.3× on Nov 11, 2026, against 5.9× a year earlier. Over the last 3 years it ranged from 2.4× to 14.1×, with a median of 6.1×.

Price to Sales Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 20266.3×+0.7
2025Dec 31, 20255.6×+2.1
2024Dec 31, 20243.5×–

More Fennec Pharmaceuticals figures

See a number that looks wrong?